NRX Pharmaceuticals (NRXP) Profit After Tax (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Profit After Tax of -$1.4 million for Q1 2026, up 74.6% year-over-year from -$801828.8 in Q1 2025, and down 450.0% quarter-over-quarter from $400000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Profit After Tax (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Profit After Tax for 10 consecutive years, with -$1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 74.6% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at -$24.5 million (down 1.51% YoY), while the FY2025 annual figure was -$28.6 million, down 13.83% from the prior year.
- Profit After Tax eased to -$1.4 million in Q1 2026 per NRXP's latest filing, from $400000.0 in the prior quarter.
- Across five years, Profit After Tax topped out at $400000.0 in Q4 2025 and bottomed at -$17.6 million in Q2 2025.
- Historically, Profit After Tax has averaged -$7.0 million across 5 years, with a median of -$6.5 million in 2024.
- Annual changes were most pronounced in 2022 — Profit After Tax tumbled 5867.52% — and 2025, when it soared 104.41%.
- NRX Pharmaceuticals' Profit After Tax stood at -$10.2 million in 2022, then soared by 57.88% to -$4.3 million in 2023, then plunged by 110.41% to -$9.1 million in 2024, then jumped by 104.41% to $400000.0 in 2025, then slumped by 450.0% to -$1.4 million in 2026.
- Business Quant data shows NRXP's Profit After Tax at -$1.4 million in Q1 2026, $400000.0 in Q4 2025, and -$5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -16.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | -5.89 Mn |
| Jun 30, 2025 | -17.58 Mn |
| Mar 31, 2025 | -5.51 Mn |
| Dec 31, 2024 | -9.08 Mn |
| Sep 30, 2024 | -1.62 Mn |
| Jun 30, 2024 | -7.90 Mn |
| Mar 31, 2024 | -6.53 Mn |
| Dec 31, 2023 | -4.31 Mn |
| Sep 30, 2023 | -6.06 Mn |
| Jun 30, 2023 | -8.72 Mn |
| Mar 31, 2023 | -5.51 Mn |
| Dec 31, 2022 | -10.24 Mn |
| Sep 30, 2022 | -9.08 Mn |
| Jun 30, 2022 | -6.98 Mn |
| Mar 31, 2022 | -13.45 Mn |
| Dec 31, 2021 | -30.41 Mn |
| Sep 30, 2021 | -37.05 Mn |
| Jun 30, 2021 | -117,000.00 |